1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
61B31718FA76D6F20652584EF0034A9D5
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/role-medical-affairs-value-based-healthcare-ecosystem-collaboration-fdama-s114-value-based-contracts?opendocument
18
19opendocument
2018.206.194.134
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Affairs Excellence

The Role of Medical Affairs in the Value-Based Healthcare Ecosystem: Collaboration, FDAMA S114 and Value-Based Contracts

ID: 5594


Features:

15 Info Graphics

12 Data Graphics

95+ Metrics

5 Narratives


Pages/Slides: 35


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “The Role of Medical Affairs in the Value-Based Healthcare Ecosystem: Collaboration, FDAMA S114 and Value-Based Contracts”

STUDY OVERVIEW

As payers and consumers place increasing emphasis on value beyond clinical effectiveness and safety, Medical Affairs organizations are developing effective strategies to succeed in this new value-based healthcare ecosystem.

Best Practices, LLC conducted this benchmarking research to examine the evolving role of Medical Affairs in the value-based healthcare ecosystem. In particular, this study benchmarks the key facets of internal and external collaborations, value based contracts, healthcare economic information and FDAMA S114 for value-centric Medical Affairs operations.

KEY TOPICS

  • Key Facets of External Collaboration & Engagement
  • Progressing Value-Based Internal Collaborations
  • Medical Affairs & Value Based Contracts
  • HEI & FDAMA S114

KEY METRICS
  • In your experience, which external stakeholders must Medical Affairs work with and how effective is Medical Affairs in working with the mentioned external stakeholders to succeed in this new value-based environment?
  • In your experience, which internal group(s) must Medical Affairs work with to succeed in this new value-based environment?
  • Roughly, what percent of product contracts are value-based contracts at your company?
  • What is the role of Medical Affairs in creating and executing value-based contracts?
  • Does your company plan to use value-based contracts in 2020?
  • How difficult has it been to gain approval for Healthcare Economic Information materials under FDAMA 114?
  • Has your group so far benefited from the amendments to S114 of FDAMA?
  • How effective are the listed Healthcare Economics Information types to your support of physicians and payers?
  • What types of healthcare economic information is approved in your company for proactive use under FDAMA 114?
  • What has been the overall impact of the FDA's S114 guidance on Medical Affairs and pharma?

SAMPLE KEY FINDINGS
  • Medical Affairs takes a supportive role with Value-based contracts. VBCs are anticipated to grow for more complicated treatments, calling for greater Medical Affairs involvement.
  • The primary benefit of FDAMA S114 has been increased proactivity with HEI for payers. Head-to-head trials were ID’d as the most essential HEI type, although only 52% of companies proactively share these.

METHODOLOGY

Best Practices, LLC engaged 70 Medical Affairs leaders from 50 companies in this research through a benchmarking survey, focus group interviews and round-table discussion.


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Medical Device; Biotech; Biopharmaceutical; Manufacturing; Consumer Products; Consulting


Companies Profiled:
Abbott; AbbVie; Alcon; Alkermes; Allergan; Astellas; AstraZeneca; Bayer; Becton Dickinson; BioCryst Pharmaceuticals; Bioventus; Boehringer Ingelheim; Cadila Pharmaceuticals; CEEK Enterprises; Eisai; Ferring Pharmaceuticals; Galderma; GlaxoSmithKline ; GRAIL; Grifols; Heron Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; La Jolla Pharmaceutical; LEO Pharma; Lundbeck; MannKind Corporation; Merck; Merck KGaA; Merck Serono; MSD; Mylan; Novartis; Orchard Therapeutics; Pacira Biosciences; Pfizer; Purdue Pharma; Roche; Sandoz; Sanofi Genzyme; Sanofi Pasteur; Santen; Sunovion; Takeda Pharmaceuticals; UCB Pharma; Ultragenyx; Vifor Pharma; ViiV Healthcare

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.